The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $2 million in grants to four life and bioscience projects in...

AMPEL BioSolutions is a precision medicine company commercializing a development pipeline of CLIA-certified gene expression tests for blood or tissue samples that provide clinical decision support.

The findings may open the door for early testing for coronary artery disease risk in patients with lupus, the researchers wrote.

The CardioGENE® lab test, only a concept for the last few years, is now ready for development for practical use as a decision support biomarker test.

The company’s new approach, through a simple blood test, will ultimately accelerate the means of providing effective treatments to the right people at the right time.

The technology is being utilized to launch a portfolio of 10+ clinical tests over the next five years to provide decision support for diseases affecting more than 50 million Americans.

Late next year, dermatologists will be able to submit a biopsy for genetic analysis and Ampel will then identify the best drugs for treatment.

AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat inflammatory skin diseases.